Beta Bionics (NASDAQ:BBNX) Shares Climb 9.9% – Still a Buy?

Shares of Beta Bionics, Inc. (NASDAQ:BBNX) shot up 9.9% on Monday. The company traded as high as $20.83 and last traded at $21.0650. Approximately 608,694 shares changed hands during trading, a decline of 48% from the average session volume of 1,170,254 shares. The stock had previously closed at $19.16.

Key Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Third-quarter results modestly exceeded expectations. Beta Bionics reported a loss of $0.52 per share, slightly better than the $0.53 consensus estimate, while revenue of $35.51 million topped the approximately $34.7 million FactSet forecast. Beta Bionics Q3 earnings report
• Neutral Sentiment: Insider selling was limited in size. Director Mark Hopman sold 821 shares for $16,420, reducing his ownership by 1.48%. He still held 54,513 shares after the transaction, so the sale is unlikely to materially affect the company’s fundamentals but may add to investor caution. SEC insider transaction filing
• Negative Sentiment: Multiple law firms publicized a securities class action against Beta Bionics. The lawsuit covers investors who purchased shares from July 30, 2025, through February 24, 2026, with a November 3, 2026 deadline to seek lead-plaintiff status. Attorneys allege the company failed to disclose material adverse information involving its iLet medical device, including a June 2025 FDA Form 483 and more than 18,000 complaints. These allegations, which have not been proven in court, follow a reported stock collapse of more than 37% and raise legal, reputational, and potential financial risks for BBNX. Beta Bionics securities lawsuit announcement

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BBNX. TD Cowen raised their price objective on Beta Bionics from $18.00 to $21.00 and gave the stock a “hold” rating in a research report on Wednesday. Jefferies Financial Group started coverage on Beta Bionics in a research report on Monday, October 12th. They set a “buy” rating and a $30.00 price objective on the stock. Truist Financial boosted their price objective on Beta Bionics from $23.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, September 24th. The Goldman Sachs Group upped their target price on Beta Bionics from $17.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Wall Street Zen raised Beta Bionics from a “sell” rating to a “hold” rating in a research report on Saturday, September 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $23.69.

Beta Bionics Stock Performance

The company has a market capitalization of $803.07 million, a P/E ratio of -10.82 and a beta of 3.39. The firm has a 50 day moving average price of $19.23 and a two-hundred day moving average price of $14.97.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, October 27th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.01. The business had revenue of $35.51 million during the quarter. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. On average, equities analysts expect that Beta Bionics, Inc. will post -2.02 earnings per share for the current year.

Insider Activity at Beta Bionics

In other news, insider Steven Russell sold 4,221 shares of the business’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $19.11, for a total value of $80,663.31. Following the sale, the insider owned 169,628 shares in the company, valued at approximately $3,241,591.08. The trade was a 2.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Christy Jones sold 6,430 shares of the stock in a transaction dated Tuesday, September 22nd. The stock was sold at an average price of $23.00, for a total transaction of $147,890.00. Following the sale, the director owned 19,564 shares of the company’s stock, valued at $449,972. This trade represents a 24.74% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 99,293 shares of company stock valued at $1,936,901. Insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of BBNX. Legal & General Group Plc acquired a new stake in Beta Bionics during the 2nd quarter valued at $62,000. The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics during the second quarter worth $172,000. Ieq Capital LLC bought a new stake in shares of Beta Bionics during the second quarter worth $229,000. Quantbot Technologies LP acquired a new stake in shares of Beta Bionics in the second quarter valued at $264,000. Finally, Man Group plc acquired a new stake in shares of Beta Bionics in the second quarter valued at $419,000.

About Beta Bionics

Beta Bionics, Inc (NASDAQ: BBNX) is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual’s glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.